CHARITY REGISTRATION NUMBER: 1155193 Nottinghamshire Leukaemia Appeal Financial Statements 31 December 2023 Nottinghamshire Leukaemia Appeal Financial Ststements Year ended 31 December 2023 Page Trustees, annual report Independent examine¢s report to the trustees Statement of financial activities Statement of financial posttion Notes to the financial statements Nottinghamshire Leukaemia Appeal Trustees. Annual Report Year ended 31 December 2023 The trustees present their report and the unaudited finarKial statements of the charity ft)r the year ended 31 December 2023. Reference and administrative details Registered charity nam¢ Noth'ngharnshire LeU￿rnia Appeal Charlty registration number 1155193 Princlpal office Biodiscovery Institule-room B209 UnNersity Park Nottingham NG7 2RD Trustee8 Mr G K Abbott Mrs M S Stoakes Dr. M J Pallis Independenl examiner Samantha C Henson ACCA 16 Meado%￿ale Creseent Clifton Nottingham NG119LZ Goveming Document The Nottinghamshire Leukaemia Appeal also known as NLA is a chanty which is an unincorporated trust governed by the Trust Deed dated 5th November 2013. Organisalional Structure Trustees meet quarterly with other mernber5 of the commrttee. Quarterly meetings are normally held lo review fund raising aclivtknes being undertaken by suppx)rters of the and to consider applications for funding of research or patient welfare. Trustees are selected on the basis of their experience and the benefrts which they can bring lo the charity. Other members are invited to join the committee based upon their knowledge and experience. The committee includes members who have relevant scientik medical kn¢)wledge required to assess research applicats"ons. Dr J Fletcher one the founding Trustees ofthe charity passed awdy on the 14 August2023.The Trustees acknowledge the work and dedicab'on Dr Fletcher has given lo the Charty. Objectivos and activities The purposes of the charity are to promote the adVanCe￿nt of the treatment of leukaemia and blood cancers by supwrting research at Nottingham UnNersty hosprtals and to promote the treatment, care and welfare of pats.enls with leukaemia and blooxj cancers at Nottingham University hospitals. Nottinghamshire Leukaemia Appeal Trustees, Annual Report Year ended 31 December 2023 Achievements and perforniance Income Income is generated from donations and proTr)ting SFrf)nsored events. The Trustees are very grateful to supporter5 of the charity in continuing to raise funds and lo members of the public who have made donations. Support Nottingham University Department of Haemalology has an established ethically approved bank of cells, DNA and RNA. The NLA provide £10,000 each year to make it possible lo process samples from new patient5, to separate and freeze Iheir Cells lo make DNA and RNA and to keep alive slcKks of blood an￿r cell lines. This resource is essential for the success of research and has resulted in four peer- reviewed joumal articles from the group in the past three years. with fvrther publications pending. James JR, Curd J, Ashworth JC, Abuh8nlash M. Grundy M, Seedhouse CH, Arkill KP. Wright AJ, Merry CLR, Thompson A. Hydrogel-Based Pr&ClinKal Evaluation of Repurposed FDA- Approved Drugs for AML. Int J Mol Sci. 2023-24141.'4235 Bailey GD, DooLan L, Baskar A. Smith LC, Seedhouse CH. Preferential transcription of the mutated allele in NPM1 mutsted acute myeloid leukaemia. Scientific Reports 2020 10{11 17695 Grundy M. A-Kaisi F. Cull J, Wlliams C. Smth D, Seedhouse CH. A same day assay predicts apoptobc response to combined BCL-2 and MCL-18H3 mimetic targeting in multip myeloma cells. EJHaem 2020 Alhuthali HM, Bradshaw TD. Lim KH, Tam KS, Seedhouse CH. The natural alkaloid Jeranbnine B has activity in acute myeloid leukaemia cells through a mechanism involving c- Jun. BMC Cancer 2020 2011) 629. Funding for the salary of Dr Martin Grundy has been extended until January 2026. Dr Gnjndy is in charge of collection and processing patient sample5 and has a wealth of exF*rience in this technically challenging area Ibloodlbone marrow Cells a￿ incredibly fragile and notoriously difficult to work with lo generate meaningful resuttsl. Research projects he is involved in inclLtde testing new genet￿ agents in leukaemia and assessing exacdy what occurs in leukaemia cells as they proliferate and how this differs to normal healthy bloc%1 cells. He has also been involved in developing models for leukaemia and myeloma lo best replicate what hap￿nS in a pab"ent. In addition, Dr Grundy is working on the role of the mutated nucleophosmin protein in leukaemia and has been using special imaging equipment lo study what happens in real time in leukaemia cells as they grow and dtvide Part of this project was presented at an international leukaemia conference (European School of Haematok)gyl in Esloril, Portugal in October 2023 and is now being written up for publication. Work is now on-going to i¢Yenl how we might specifically target and kill the mutant cells wthout killing the nomial cells. PhD students Lara Doolan and Mays Abuhantash completed their NLA-fvnded Betty Barton sludentships and graduated in 2023. Their work focused on models of bthd cancers which can be used to efficiently and quickty test new drugs to identify which have potential to kill cancer cells. Novel findings on how different leukaemia's may beeome resistant to therapies have also been generated and work within the Blood Can￿r and Stem Cell Group in Notbngham is continuing to develop these areas of research. The work supported knlfils the objective of the NLA lo pronv)te the advancement of research Into the treatment of leukaemia in NottJ"nghamshire. The quality of the funded research is evident by publication in international peer-reviewed joumals (three articles published in 2018. one in 2019. three in 2020, one in 2023 with several others in preparation). Financial review Nottinghamshire Leukaemia Appeal Trustees, Annual Report Year ended 31 December 2023 Donations and legacies received were £4,04812022.. £1.340). Fund raising events generated net income of £42,675 (2022." £28,204). Running costs were kept to 8 minimum at £98812022= £1.5071. No payments12022'. Nil} or other benefits were made lo trustees and committee members. Awards and donab.ons made were £113,97212022.' £13.000). UnrestrKted reserves were £63,57412022". £140,147). The trustees. annual report was approved on 6￿ September 2024 signed on beha￿ of the trK)ard of trustees by.. Mr G K Abbott Trustee Nottinghamshire Leukaemia Appeal Independent Examinerfs Report to the Trustees of Nottinghamshire Leukaemia Appeal Year ended 31 December 2023 I report to the trustees on my exarnination of the financial statements of Nottinghamshire Leukaemia Appeal I'lhe charity'l for the year ended 31 Deeernber 2023_ Responsibilities and basis of report As the Iruslees of the charity you are responsible for the preparation of the financial statements in accordance wrth the requirements of the Charities Act 2011 I'the Act'}. I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 14515}Ib) of the ACL Independenl oxaminerfs slatement I have completed my examination. I conffmi that no material matters have come lo my attention in connection with the examination gwing me cause lo believe that in any material respect.. accounting records were not kept in resFtcl of the charity as required by section 130 of the Act", or the financial statements do not accord with those records" the financial ststements do not compty wrth the applicabie requireffEnts eoneeming the form and content of aecounls Set out in the chartts.es (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fairf view which is not a matter considered as part of an independent examination. I have no concem5 and have come across no other matters in connection with the examination lo which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached. anlha C Henson ACCA Independent Examiner 7tr October 2024 Nottinghamshire Leukaemia Appeal Statement of Financial Activities Year ended 31 December 2023 2023 unreStr￿ted funds Total funds Total funds 2022 Note Incoming Rosources Income and endowments Donations and legacies Funding raising actwilies Investment incorre 4,048 44,375 1.664 4,048 44,375 1,340 29,904 48 Total income 50,087 50.087 31,292 Resources Expended Costs Costs of fund-raising aeb'vities Charitable donations 1,700 124,960 1,700 124,960 1,700 14,507 Total Outgoings 126,660 126,660 16.207 Ngt Ideficitysurplus {76,573) 176,5731 15.085 Reconciliation of funds Total funds brought forward Total funds carried forward 140.147 140, 147 125,062 63,574 63,574 140,147 The statement of financial activities includes all gains and losses recognised in the year. All ineome and expenditure is defive from continuing activibes. Nottinghamshire Leukaemia Appeal ststement of Financial Position 31 December 2023 2023 2022 Note Current Assets Cash at bank and in hand 221,922 206,900 206,900 Total current assets 221,922 Creditots: amounts falling due within one year 10 82,366 51,010 Net Current Assets 139,556 158.890 Creditors.. amounts falling due after one year 10 75.982 15,743 Total Net Assets 63.574 140,147 Funds of the charity Unrestrtcted fvnds 63,574 140,147 Total charity funds 63,574 140.147 These financial statements were approved by the tr￿ard of trustees and authorised for issue on 61h September 2024, and are signed on behalf of the board by: Mr G K Abbott Trustee Nottinghamshire Leukaemia Appeal Notes to the Financial Statements (contin Year ended 31 December 2023 General infomiation The charity is a public benefit enkn'ty and a registered charity in England and Wales and is unincorporated. The address of the principal office is Biodkscovery Instr(ule-room B209 Unive15ity Park,Nottingham, NG7 2RD. Staternent of compliance These financial statements have been prepared in wmpliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland., the Statement of Recommended Practi￿ applicable to charities preparing their accounts irb accordance with the Financial Reporting Stsndard applicable in the UK and Republic of Ireland IFRS 1021 (Charities SORP IFRS 1021} and the Charities Act 2011. AccountSng pollcles Basis of preparation The financial stslements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured al fair value through income or expendI￿re. The financial statements are prepared in sterling. which is the functional currency of the entity. Golng concern There are no material uncertainties about the chanty's abilty to continue. Judgements and key sources of estlmalion uncertainty The preparation of the financial statements requires management to make judgements. estimates and assumptions that affeel the amounts reported. These esb"mates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Incorning resources l incoming resources are induded in the statement of financial actNities when ents1￿ment has passed lo the charity." rt is probable that the economic benefits associated wrth the transaction wll flow to the charity and the amount can be reliably measured. The following specific policies are applied lo particular categories of income.. income from donations or grants is recognised when there is evidence of entitlement lo the gif( receipt 15 probable and rts amount can be measured reliabty. legacy in￿rne is re￿gnised when receipt is probable and entiuement is established. income from donated goods is measured at the fair value of Ihe goods unless this is impractical lo measure reliably, in which case the value is derived from the cost to the donor or the eslimaled resale value. Donated facilities and services are recognised in the accounts when received if the value can be reliabty measLsred. No amounts are included for the ontribution of general volunteers. Nottinghamshire Leukaemia Appeal Notes to the Financial Statements Year ended 31 December 2023 Re$ource$ expended Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is classified under headings of the statement of financial aelNilies to which rt relates". expenditure on raising funds includes the costs of all fundraising actNtties, events, non- charitsble trading 2eb"vities. and the sale of donated goods_ expenditure on charitable activitEs includes all costs incurred by a charity in undertaking aclNities that further ils charitabk aims for the benefit of its beneficiaries. including those support costs and costs rdating to the govemance of the chanty apportioned to charitable aclivikne5. other expenditure includes all expenditure that is neither related lo raising fvnds for the charty nor part of its expenditure on charitable activib"e5. All costs are allocated to expenditure categories refle¢bng the use of the resource. Direct costs attributable lo a single activity are allocated directly to that activity. Shared costs are apportioned be￿een the activities they ¢ontribute to on a reasonable. jusbfiable and consistent basis. Donations and legacies Total Funds Total Funds 2023 2022 Donations Donations and Legacies 4,048 1,340 Fund raising activities Total Funds Total Funds 2023 2022 Fundraising acb"vities 44.375 22,904 Investment income Totsl Funds Total Funds 2023 2022 Bank interest receivable 1,664 48 Costs of fundrnising activilies Total Funds Total Fund5 2023 2022 Fund raising Costs 1,700 1,700 Nottinghamshire Leukaemia Appeal Notes to the Financial Statsments (contin Year ended 31 December 2023 Expenditure on charitable activities Total Funds Total Funds 2023 2022 Charity donations and support Administration and support costs 113.972 988 13,000 1,507 114.￿0 14,727 Trustee remuneratlon and expenses No remuneration or other benefits were received by the trustees. 10. Creditors Credttors include committed support on 31 D￿ernber 2023 of £156.648 {2022.' £65,813) of which £75,982 (2022.. £15,743) is due after Tr￿re than one year.